Companies: 10,795·Total market cap: $144.5T
Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc.

EPRX.TOTSXHealthcare● Active
$8.58
+$0.19(+2.26%)
Market Cap$308344042
P/E Ratio
52W High$12.86
52W Low$5.2
Overview

Eupraxia Pharmaceuticals Inc. (EPRX.TO) · Balance Sheet

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · EPRX.TO · as of 2026-06-10

Financial statements

Total Assets · Total Liabilities · Equity
Breakdown2025-122024-122023-122022-122021-12
Assets
Cash & ST Investments$0.08B$0.03B$0.02B$0.02B$0.03B
Net Receivables$0.00B$0.00B$0.00B$0.00B$0.00B
Inventory$0.00B$0.00B$0.00B$0.00B$0.00B
Total Current Assets$0.08B$0.03B$0.02B$0.03B$0.03B
PP&E Net$0.00B$0.00B$0.00B$0.00B$0.00B
Goodwill$0.00B$0.00B$0.00B$0.00B$0.00B
Intangible Assets$0.00B$0.00B$0.00B$0.00B$0.00B
Total Assets$0.09B$0.03B$0.02B$0.03B$0.03B
Liabilities
Short-Term Debt$0.00B$0.00B$0.01B$0.00B$0.00B
Accounts Payable$0.00B$0.00B$0.00B$0.00B$0.00B
Total Current Liabilities$0.01B$0.00B$0.02B$0.00B$0.00B
Long-Term Debt$0.00B$0.00B$0.00B$0.01B$0.01B
Total Liabilities$0.01B$0.00B$0.02B$0.01B$0.01B
Stockholders Equity
Retained Earnings($0.17B)($0.13B)($0.08B)($0.10B)($0.07B)
Total Stockholders Equity$0.08B$0.03B$0.00B$0.01B$0.02B
Total Liab & Equity(computed)$0.09B$0.04B$0.02B$0.03B$0.03B
Debt Summary
Total Debt$0.00B$0.00B$0.01B$0.01B$0.01B
Net Debt($0.08B)($0.03B)($0.01B)($0.01B)($0.01B)

Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B

Explore more Eupraxia Pharmaceuticals Inc. data

About Eupraxia Pharmaceuticals Inc. (EPRX.TO) Balance Sheet

Eupraxia Pharmaceuticals Inc. (EPRX.TO) balance sheet shows total assets of $0.09B with cash of $0.08B. Total liabilities are $0.01B, total debt $0.00B, and stockholders equity $0.08B.

Frequently asked questions

EPRX.TO · 4 questions

Eupraxia Pharmaceuticals Inc. has total debt of $0.00B with net debt of ($0.08B).

EPRX.TO total debtnet debtdebt to equity

· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10